Mahmoud Eslami-Farsani, MD
Cardiology · Santa Ana, CANPI 1487659637
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 35 manufacturers, the largest accounting for just 15.0% — the pattern of someone who eats at a lot of different presentations.
Across 242 payments — averaging $22.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$801
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$582
- Medtronic$454
- Biotronik Inc.$409
- Johnson & Johnson$389
- Amgen$385
- plus $2K from 29 others
Across 26 payments — averaging $15,580 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Edwards Lifesciences$405K
What the payments were for
- Food & beverage$5,23498%
- Education$1072%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 42 | $801 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 33 | $582 |
| Medtronic(2 entities) | 16 | $454 |
| Biotronik Inc. | 12 | $409 |
| Johnson & Johnson | 23 | $389 |
| Amgen | 14 | $385 |
| E.r. Squibb & Sons, L.L.C. | 19 | $320 |
| Pfizer | 9 | $209 |
| Merck | 10 | $194 |
| Shockwave Medical, Inc | 1 | $159 |
| Novo Nordisk | 7 | $145 |
| Boston Scientific | 6 | $119 |
| Recor Medical Inc | 5 | $111 |
| Scpharmaceuticals Inc. | 5 | $105 |
| Siemens Medical Solutions USA, Inc. | 1 | $103 |
| Sanofi-aventis U.S. LLC | 5 | $92 |
| Otsuka America Pharmaceutical, Inc. | 4 | $89 |
| Abbott | 3 | $77 |
| Bayer | 3 | $63 |
| Tactile Systems Technology Inc | 2 | $61 |
| Boehringer Ingelheim | 3 | $51 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $50 |
| Cathworks, Inc. | 3 | $50 |
| Abiomed | 1 | $47 |
| Cardiva Medical, Inc. | 1 | $41 |
| Cardiovascular Systems Inc. | 2 | $38 |
| Edwards Lifesciences | 1 | $37 |
| Venclose Inc. | 2 | $32 |
| Cardinal Health 200 LLC | 1 | $30 |
| Cleerly, Inc. | 1 | $20 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Bsn Medical Inc | 1 | $16 |
| Esperion Therapeutics, Inc. | 1 | $16 |
| Getinge USA Sales, LLC | 1 | $14 |
| Bardy Diagnostics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,341 in reported general payments places this provider in the 80th percentile of 156 cardiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 414 | $523,186 |
| XareltoRivaroxaban | 231 | $300,324 |
| EntrestoSacubitril/Valsartan | 79 | $70,893 |
| Repatha SureclickEvolocumab | 42 | $49,828 |
| FarxigaDapagliflozin Propanediol | 33 | $38,348 |
| Praluent PenAlirocumab | 48 | $33,509 |
| BrilintaTicagrelor | 32 | $26,222 |
| JardianceEmpagliflozin | 14 | $16,737 |
| VascepaIcosapent Ethyl | 20 | $14,766 |
| OzempicSemaglutide | 12 | $9,624 |
| Metoprolol Succinate | 636 | $9,450 |
| EdarbiAzilsartan Medoxomil | 12 | $9,400 |
| NexlizetBempedoic Acid/Ezetimibe | 11 | $8,384 |
| Rosuvastatin Calcium | 409 | $7,582 |
| JanuviaSitagliptin Phosphate | 11 | $7,082 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $209 | $523,186414 claims |
| Johnson & JohnsonXarelto | $389 | $300,324231 claims |
| NovartisEntresto | $801 | $70,89379 claims |
| Boehringer IngelheimJardiance | $51 | $16,73714 claims |
| Novo NordiskOzempic | $145 | $9,62412 claims |
| Esperion Therapeutics, Inc.Nexlizet | $16 | $8,38411 claims |
| MerckJanuvia | $194 | $7,08211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 156 cardiology providers in California.
Other cardiology in Santa Ana
- Anil ShahSanta Ana$49K
- Thomas KimSanta Ana$47K
- Amer ZarkaSanta Ana$6K
- Stephen CohenSanta Ana$6K
- Bahram EslamiSanta Ana$4K
- Paul MeltzerSanta Ana$2K
- Norman LeporBeverly Hills$1.9M
- Sanjay KaulLos Angeles$1.1M
- Ramtin AgahMountain View$361K
- Jamshid MaddahiLos Angeles$59K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.